Booster Effect of mRNA Vaccine on Antibody Response for SARS-CoV-2 After Complete Vaccination With Sinos

NCT ID: NCT05213455

Last Updated: 2022-03-02

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2022-03-15

Brief Summary

In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for mass level immunization. Though these vaccines were approved by WHO, their efficacy had been questioned.

Now after recommendation of booster doses, we aim to see the effect of mRNA vaccine as a booster dose after Sinovac and Sinopharm in terms of antibody response. (IgG RBD SARS CoV2)

Detailed Description

In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for mass level immunization. Though these vaccines were approved by WHO, their efficacy had been questioned.

Now after recommendation of booster doses, we aim to see the effect of mRNA vaccine (BNT162b2, pfizer) as a booster dose after Sinovac and Sinopharm in terms of antibody response. (IgG RBD SARS CoV2).

The antobody IgG RBD levels will be checked before the booster dose and then after 3 weeks of the booster.

Conditions

Vaccine Reaction

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

booster vaccine for COVID 19

The effect of Booster vaccine will be seen in participants in terms of antibody response IgG

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• people who have received two doses of sinopharm or sinovac and six months have passed after the second dose

Exclusion Criteria

• people getting one shot of sinopharm or sinovac or got vaccine other than sinopharm and sinovac.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lahore General Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Amina Asif, M.Phil

Role: PRINCIPAL_INVESTIGATOR

Lahore General Hospital

Muhammad Irfan Malik, FRCP

Role: PRINCIPAL_INVESTIGATOR

Lahore General Hospital

Locations

Lahore General Hospital

Lahore, Punjab Province, Pakistan

Countries

Pakistan

Other Identifiers

LGH010

Identifier Type: -

Identifier Source: org_study_id